Large U.S. cancer trial to match genetic glitches to targeted drugs

CHICAGO, June 1 (Reuters) – The National Cancer Institute in July will start enrolling patients in a clinical trial seeking to match the underlying genetic defect driving a person’s tumor with one or more of 20 approved or experimental drugs targeting that gene.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s